Threat of superbugs looms large with few new drugs in the pipeline

Report highlights some 'game-changing' vaccines but pharma firms still failing to invest in antibiotic development, writes The Telegraph, as the Access to Medicine Foundation publishes it latest AMR Benchmark.

The Benchmark's Research Programme Manager Fatema Rafiqi called for companies to treat the threat of AMR with more urgency, telling the publication: “If the same investment was made in the slow-burning pandemic of AMR as in the fast-burning pandemic of Covid we could tackle this threat."

Read the full article in The Telegraph.